Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT)
share announcement

Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 1339

Special Issue Editor

Dr. Monzr M. Al-Malki

E-Mail Website
Guest Editor
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA
Interests: stem cell transplantation; multiple myeloma; lymphoma; leukemia; bone marrow diseases; myelodysplastic syndromes; acute lymphoblastic leukemia

Special Issue Information

Dear Colleagues,

Although hematopoietic cell transplantation (HCT) is potenitally curative for hematological malignancies, it can often lead to several complications that can be life threatening. One of the major causes of mortality and morbidity after HCT is graft-versus-host disease (GVHD). Despite the signifcant advances in GvHD prophylaxis, the incidence of GVHD remains high with around 10-15% of cases being severe. High-dose corticosteroids remains the cornerstone for GVHD therapy. The response rates have been disappointing, and steorid-refractory GvHD prognosis remains dismal. This Special Issue welcomes original research articles and reviews.  Research areas of interest include (but are not limited to) the following:

  • Incidence of GVHD;
  • Risk factors of GVHD;
  • Treatment outcomes of GVHD;
  • Complications;
  • Biomarkers for GVHD.

I look forward to receiving your contributions.

Dr. Monzr M. Al-Malki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • graft-versus-host disease (GVHD)
  • hematopoietic stem cell transplantation
  • risk factors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1315 KiB  
Article
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)
by Hoda Pourhassan, Tina Nguyen, Dongyun Yang, Salman Otoukesh, Shukaib Arslan, Amanda Blackmon, Vaibhav Agrawal, Idoroenyi Amanam, Brian Ball, Paul Koller, Amandeep Salhotra, Ahmed Aribi, Pamela Becker, Peter Curtin, Andrew Artz, Ibrahim Aldoss, Haris Ali, Forrest Stewart, Eileen Smith, Anthony Stein, Guido Marcucci, Stephen J. Forman, Ryotaro Nakamura and Monzr M. Al Malkiadd Show full author list remove Hide full author list
Cancers 2024, 16(23), 3912; https://doi.org/10.3390/cancers16233912 - 22 Nov 2024
Viewed by 1030
Abstract
Background: The standard first-line treatment for acute graft-versus-host disease (aGvHD) is systemic, high-dose glucocorticoids which have historically had limited responses. Combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab (a TNF-α inhibitor) and basiliximab (an IL-2 receptor blocker) has had limited discussion [...] Read more.
Background: The standard first-line treatment for acute graft-versus-host disease (aGvHD) is systemic, high-dose glucocorticoids which have historically had limited responses. Combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab (a TNF-α inhibitor) and basiliximab (an IL-2 receptor blocker) has had limited discussion in the literature. Methods: Sixty patients with steroid-refractory aGVHD were analyzed. The primary objective was to determine the overall response rate (ORR) for CCBT. Secondary outcomes included non-relapse mortality (NRM) and overall survival (OS). Results: ORR for CCBT at day 7, 14, and 28 were 28.3% (17/60; CR 5.0%/PR 23%), 38.3% (23/60; CR 11.3%/PR 27%), and 38.3% (23/60; CR 23.3%/PR 15%), respectively. Patients who received ruxolitinib prior to CCBT had lower ORR (25% CR = 15%/PR = 10%) compared to those who did not (47.5% CR = 27.5%/PR = 20%). In patients with and without ruxolitinib initiated prior to CCBT, NRM at 6 months was 60% (95% CI, 34.5–78) and 47.5% (95% CI, 31–62), while OS at 12 months was 30% (95% CI, 12–50) vs. 40% (95% CI, 25–55), respectively. Conclusions: CCBT has shown potential efficacy in steroid-refractory GI aGvHD, and given the observed ORR when used as second-line therapy, CCBT could serve as an acceptable alternative for patients who are ruxolitinib-intolerant. Ruxolitinib-refractory GI GvHD remains an area of unmet need and CCBT can provide salvage therapy for some patients. Full article
(This article belongs to the Special Issue Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop